Introduction
Cardiac transplantation is an accepted therapy for end-stage cardiac disease. While improvements have been made in early graft survival rates, largely due to the introduction of potent immunosuppressive regiments, primary graft failure and chronic rejection still present significant challenges to graft survival 1, 2 . The majority of organs utilized for transplantation are acquired from brain dead donors. Evidence from clinical and experimental studies indicate that brain death (BD) is a significant contributing factor to inferior graft function and is detrimental to the outcome of kidney, heart, lung and liver transplants 3, 4 .
Brain death evokes a potent Cushing's response that leads to hemodynamic fluctuations, global organ ischemia, hypothermia, coagulopathies, hormone depletion, and electrolyte abnormalities [4] [5] [6] . In addition to these physiological and hormonal imbalances, recent studies have demonstrated that components of the immune system activate donor organs rendering them proinflammatory prior to implantation [5] [6] [7] [8] [9] .
One effector arm of the immune system that has attracted some attention in BD-induced inflammation is the complement system. Complement plays an important role in the pathogenesis of many inflammatory disease conditions when excessively or inappropriately activated 10 . Biological effector functions of complement are mediated through a variety of cleavage fragments that directly or indirectly promote inflammatory cell migration, activation, cytokine release, cell lysis and adaptive immune cell modulation [11] [12] [13] . In kidney transplantation, BD is associated with increased levels of complement activation [14] [15] [16] [17] [18] . Complement activation in the BD donor has also been shown to correlate with a poorer patient outcome after renal transplantation 19 . Using a rat model of BD, treatment of the BD donor with a systemic complement inhibitor, sCR1, prior to and 1 hour post BD induction, resulted in improved renal global organ ischemia, hypothermia, coagulopathies, hormone depletion, and elec ec ctr tr ro ol o yt yt yte e abnormalities [4] [5] [6] . In addition to these physiological and hormonal imbalances, recent studies have de emo mo mons ns nst tr trat at ated ed ed tha ha at t t co components of the immune sys ys yste em m activate don on nor o o org rg rga a ans rendering them pron nfl la am ammatory p pri ri r o or r t to o im m mpl pl plan an anta ta tati tion on n 5-9 5-9 5 .
On One e e ef e effe fec c cto or or a arm rm m o of th th the im im immu m mun ne ne s s sys ys yst t tem m m th th hat at t ha ha as at at attr tr trac ac cte te t d d d so so some me me a att tten en nti tion on o i i in n n BD BD D-i ind ndu u uce ed ed nflammation n i i is s s th th he e e co co comp mp m le le eme me m nt nt nt s s sys ys ste t m. m. m C C Com om omp p ple le eme me ment nt n p p pla la lays ys ys a a an n n im im impo po port rt rtan an ant t t ro ro role le e i in n n th th the e transplant outcomes 17 . Finally, in developing a mouse model of BD, we demonstrated that deficiency of C3, a central protein through which all complement activation pathways operate, is protective against BD-associated cardiac injury and inflammation 20 .
The above studies demonstrate that complement is activated in the BD donor, and indicate that BD-induced complement activation negatively impacts post-transplant outcome, at least with regard to renal transplantation. These findings therefore raise the possibility that therapeutic manipulation of the complement system may be a viable treatment rationale to ameliorate the detrimental impact of BD on donor organs. Nevertheless, the complement system has important physiological roles, not least in host immunity to infection, and systemic complement inhibition would not be without risk, especially in an already immunosuppressed transplant recipient. In the sCR1 study referenced above, the authors bypass the potential risk of systemic inhibition in the recipient by treating the organ (kidney) donor. However, donor management remains a controversial topic of debate due to organ-specific and systemic effects.
Interventions that improve kidney organ quality may not similarly improve cardiac or other organ outcome. For example, complement has important regenerative functions in the liver [21] [22] [23] , and inhibition of complement in the donor may impact the repair and regenerative capacity of the liver after transplantation. In addition, C3a and C5a anaphylatoxins can have distinct opposing hemodynamic roles, with increased C3a activation causing hypertension and C5a causing hypotension 24 , and infusion of complement inhibitors directly to the donor may further exacerbate the already complicated donor hemodynamic management.
With these issues in mind, we used our mouse model of BD to demonstrate that hearts from BD donors fared worse than hearts from living donors in terms of post-transplant injury, inflammation and allograft survival. We also investigated the therapeutic effect of treating the complement inhibition would not be without risk, especially in an already immun un nos s sup up ppr pr pres es esse se sed d d ransplant recipient. In the sCR1 study referenced above, the authors bypass the potential risk of y yst st tem em emic ic ic i i inh nh nhib i ibit tio io on n n in i the recipient by treating the he he o o organ (kidney) ) do d no no or r. r. H However, donor m man na nagement r rem em ma ai ins ns a a c c con on ontr tr rov ov over ersi si s a al al t top op pic o o of d deba at te e d due ue ue t to o o or rga gan-n-sp pec ec cif fic ic a an and d d sy syst s s em em emi ic i e e ef ff ffe e ect t ts.
n nte te terv rv ven en e ti tion on ons s s th tha a at i i imp mp mpro ro ove ve k kid id i ne ne ney y y or o orga ga an n n qu qu qua a alit it ity y y ma ma may y y n no not t t si si simi mi mila la lar rl rly y im im imp p pro ov ve e ca ca c rd rd r ia ia ac c c or o oth th her er organ outcom m me. e. e F For or or e exa xa xamp mp ple le le, , , co o omp mp mple le l me me ment nt nt h h has as as im im impo po port rt r an n nt t t re re rege ge gene ne nera ra r ti ti ive ve ve f f fun un unct ct ctio ions ns ns i i in n n th th the e liver 21 25 , is that complement is inhibited locally at sites of complement activation but not systemically, and complement-dependent host defense mechanisms are not disrupted.
Methods
Male C57BL/6, BALB/c and C57BL/6 pan-GFP mice (latter kindly gifted by Dr Okabe, Japan), recipients. Recipients in CR2-Crry treatment groups received a single intraperitoneal injection of 0.25 mg CR2-Crry. CR2-Crry was prepared and purified as previously described 26 . Cardiac grafts and serum were harvested 48 hours post transplantation.
performed according to approved experimental protocols, in accordance with inst st tit itut ut u io o ona na nal l l an an anim imal care guidelines of the Medical University of South Carolina and Harvard Medical School.
I Is Isog og ogra ra aft s s stu tu tudi d es comprised 5 experimenta a al l l d do onor groups f for or o the he e t t th he herapeutic studies (n=6):
Brain death induction
Donor animals were placed in supine position. Blood pressure was monitored continuously via a 30G cannula inserted into the left carotid artery and connected to a monitoring transducer system (Biopac Systems Inc., Santa Barbara, CA, USA). After tracheotomy, a ventilation cannula was inserted and animals connected to a rodent ventilator (Harvard Apparatus Inc., Holliston, MA, USA) with a respiration rate of 120/min, and a tidal volume 300-400 L (12-16 L/g). Animals
were subsequently placed in a prone position and the parietal bone exposed via midline skin incision. A 4 F balloon catheter was inserted via a paramedian borehole and inflated over a 10 minute period achieving irreversible pontine ischemia by brain stem compression. In shamoperated controls, the balloon catheter was left in place without inflation during the entire observation period. Brain death was verified by an initial blood pressure peak (Cushing-reflex) and transient spontaneous muscular fasciculation of the rear limbs during brain stem compression, and subsequent absence of spinal reflexes. Afterwards, reflex-testing was performed at 10 minute intervals. In cases where persisting spinal reflexes were present for more than 10 minutes, animals were excluded from the study. Donors experiencing prolonged hypotensive periods below 50 mmHg for > 20 minutes were also excluded. 
Heart transplantation
Cardiac grafts were placed into an infrarenal location via an abdominal midline incision by microsurgical technique 26 . Graft function was assessed by manual palpation.
Histology operated controls, the balloon catheter was left in place without inflation during t t the he he ent nt ntir ir ire e e observation period. Brain death was verified by an initial blood pressure peak (Cushing-reflex)
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Tissue blocks were placed in 10% buffered formaldehyde solution for 48 h before being embedded in paraffin. Heart sections were stained with H&E, and scored using a histology scoring system on a scale of 0-3 previously described 26 . The results are expressed as cumulative scores from 0 to 12. To further quantify evidence of cardiac damage, we measured cardiac enzyme troponin I activities as an index of cardiac damage (Life Diagnostics, West Chester, PA).
Complement deposition
Paraffin-embedded heart tissue sections (4 m) were stained for the presence of C3d by immunohistochemistry using an Ab directed against C3d (R&D Systems, Volcano, CA).
Immunohistochemistry was scored semiquantitatively as described 27 .
Immunohistochemistry
Neutrophils (GR1; BD Pharmingen, San Jose, CA) and macrophages (mac-3; BD Pharmingen)
were assessed by immunohistochemistry and quantified by computerized image analysis (Zeiss Microsystems, USA). For cell fate studies, sections from GFP + donor hearts at 0, 6 and 48 hrs post transplantation were stained with antibodies to either GR1 or MAC-3, and visualized using anti-rat 555. Sections were counterstained with TO-PRO-3 (Molecular Probes, OR, USA) and imaged using a Leica TCS-SP2 Confocal microscope (Leica Microscope, USA).
ELISA Cytokine and Myeloperoxidase Analysis (MPO)
MCP-1, KC, IL-1 , MIP-2 and MPO were measured in heart grafts harvested at 48 hrs posttransplantation. Hearts were homogenized, and protein extracted from tissues as described 26 .
Chemokine/cytokine and MPO levels were measured using ELISA kits (R&D Systems, USA, and Northwestern Life Science Specialties, USA) in accordance with the manufacturer's recommendations.
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Results
Experimental studies:
Brain Death
Irreversible pontine ischemia was achieved by balloon catheter inflation of 82±27 L saline without significant differences between study groups. After induction of BD, animals were followed for three hours. On completion of BD procedure, hearts were harvested from donor animals and transplanted into mice that were randomized into four groups: CR2-Crry treated and untreated groups for isograft transplantation, and CR2-Crry treated and untreated groups for allograft transplantation. To ensure that effects of CR2-Crry on isograft and allograft transplantation groups were associated with therapy, and not donor organ quality, we analysed the mean arterial pressure profiles from each individual donor. Figure 1 shows the mean arterial pressure of brain dead donor mice that are grouped into their post transplant treatment groups.
We performed a general linear mixed model analysis to determine whether there were any differences in quality of donor organs between groups. Results of the general linear mixed models indicated that for both the isograft and allograft experiments, there were no significant differences in mean MAP values over time between the BD and BD+CR2-Crry groups. In the untreated grou ou ups ps ps f f for or or iso so sogr g af af aft t t tr t t an an ansp sp s la la lant t tat at a io io ion, n, n an an and d d CR CR CR2-2-Cr Cr Crry ry ry t t tre re eat at ated ed d a a and nd nd u u unt nt ntre re r at at ated ed ed g g gro ro roup u s for isograft experiment (Fig 1A) , the mean difference between groups MAP values over time was 0.8 mmHg (95% confidence interval: -9.1 to 10.6, p=0.87). In the allograft experiment (Fig 1B) , the mean difference between groups MAP values over time was 0.7 mmHg (95% confidence interval: -7.2 to 8.7, p=0.83) (Fig 1A & B) . Cold and warm ischemic times of the cardiac grafts were similar in all experimental groups.
Brain death exacerbates ischemia reperfusion injury
Hearts procured 48 hours post-transplant from recipients that received either living or BD donor hearts exhibited key features associated with ischemia reperfusion injury (IRI), including myocyte damage in the epicardium, endocardium, and myocardium. Transplanted hearts also
showed evidence of inflammatory cell infiltration, as well as endothelial activation denoted by endothelial swelling. However, histological scores of injury and inflammation were higher in grafts from recipients that received BD donor hearts (Fig 2A) . In accordance with these histological observations, serum levels cardiac troponin I, an index of cardiac cell damage, was also significantly higher in recipients receiving BD donor hearts compared to recipients receiving living donor hearts (Fig. 2B) .
Treatment of recipients with a targeted complement inhibitor protects both living and brain dead donor hearts from IRI
Complement is known to play a role in IRI of multiple organs, and since the data above show that cardiac IRI is exacerbated in BD donor hearts, we investigated the effect of a targeted complement inhibitor on IRI following the transplantation of both living and BD donor hearts.
Recipients were treated with 0.25mg of CR2-Crry immediately post reperfusion. CR2-Crry reduced cardiac injury profiles in hearts transplanted from both living and BD donors ( Fig. 2A &   B) . Of note, CR2-Crry treatment reduced injury in living and BD hearts to levels at or below that howed evidence of inflammatory cell infiltration, as well as endothelial activati tio o on d d den en not ot oted ed ed b b by y endothelial swelling. However, histological scores of injury and inflammation were higher in gr graf af fts ts ts f f fro rom m m re re ecipi pi pie en ents that received BD donor he e ear a a t ts s (Fig 2A) . In n ac a a co ord rd rda a ance with these h hi hist t to ological obs bse e erv va vati ti io on ons s, s, s s ser er rum u um le le ev ve vels s c c card di iac c c tro o op po oni i in n I, I, a a an n i ind nd dex x x o of f f ca card rdia ia ac c c ce cell ll ll d d dam am amag g ge e, w w wa a as al lso so o s s sig ig igni nifi fi ica ca cant ntly ly y h h hig igh h her r r in in re ec ecip ip ipi i ien en ent ts ts r r rec ec cei ei eiv vi ving ng g B BD D do do ono no or r r h h hear ar arts ts c co o omp mp mpar ared ed e t t to o o re re r ci ci ipi pi pien nt t ts r r rec ece e eiv vi ving n iving donor h h hea ea eart rt ts s s ( ( (Fi Fi ig. g. g 2 2B B B). ). ).
seen in living and sham BD transplanted hearts without inhibitor treatment.
Donor brain death exacerbates post transplant complement deposition in grafts
In a previous report, we demonstrated that complement is activated as a consequence of BD and subsequent animal management 20 . We therefore investigated whether the exacerbated injury seen in BD donor hearts after transplantation is associated with increased C3 deposition.
Immunohistochemistry demonstrated the presence of the complement activation product C3d in all grafts analyzed, with staining present on endothelial cells lining capillaries and in areas of myocyte damage (Fig. 3A) . Quantification of C3d deposition revealed significantly higher levels of C3d in grafts from BD donors compared to grafts from living donors. Furthermore, treatment of recipients with CR2-Crry significantly reduced C3d deposition in both living and BD donor hearts, with C3d levels in BD donor grafts reduced to that seen in living donor grafts from recipients that did not receive inhibitor (Fig. 3B) . Of note, C3d levels in grafts from both living and BD donors correlated with histological injury scores.
Complement inhibition attenuates inflammatory cell infiltration
We next investigated whether the exacerbated complement activation seen in BD donor grafts was associated with increased infiltration of neutrophils and macrophages. Correlating with the histological determination of injury and C3d deposition, levels of MPO were significantly elevated in grafts from BD donors compared to grafts from living donors. Furthermore, treatment of recipients with CR2-Crry significantly reduced MPO levels in grafts from both living and BD donors (Fig. 4A) .
To further quantify specific inflammatory cell infiltration, we analyzed graft sections by immunohistochemistry for neutrophils (anti-GR1) and macrophages (anti-MAC-3). Neutrophils and macrophages were present in all groups, with infiltrating cells present in the epicardial, of recipients with CR2-Crry significantly reduced C3d deposition in both living a a and nd d B B BD D D do do dono no n r r hearts, with C3d levels in BD donor grafts reduced to that seen in living donor grafts from e eci ci ipi pi pien en ents ts ts t t tha ha hat t di di id d d n not receive inhibitor (Fig. 3B B) . endocardial and myocardial compartments between myocytes, and localized in larger numbers at the epicardial surface. The distribution of both cell types was not significantly different between groups (not shown). Quantification revealed significantly higher numbers of both neutrophils and macrophages in BD donor grafts compared to living donor grafts, and CR2-Crry treatment reduced neutrophil and macrophage numbers in both living and BD donor grafts (Fig 4B and C) .
Donor brain death increases intragraft pro-inflammatory cytokine expression
Previous 
Donor brain death significantly reduces allograft survival
To further assess the impact of BD in transplantation and the therapeutic potential of targeted complement inhibition in a more clinically relevant setting, we performed allograft transplants.
Hearts from C57BL/6 living, sham or BD donors were transplanted into BALB/c recipients. In 
Clinical studies: complement activation and immune cell infiltration
To address the clinical relevance of our findings, complement activation was assessed in human tru-cut biopsies of donor hearts prior to implantation and ten minutes post reperfusion. We analyzed complement deposition in 8 biopsies from human hearts taken from BD donors, and in 4 biopsies from human hearts taken from living (domino) donors (from cystic fibrosis patients undergoing combined heart-lung transplantation). Using accepted guidelines for histology scoring of C4d and C3d deposition, biopsies were deemed positive if 2+ immunostaining was noted 27 . In biopsies taken from BD donors before implantation, 5/8 were positive for C4d and Fig. 8A and B) . Of note, the number of MAC387 and CD68 positive cells in grafts from BD donors remained elevated for at least a week post-transplant, whereas in living donor grafts the level of positive cells were not significantly different at 10 minutes postreperfusion than in normal heart controls (p> 0.05). We did not have access to one-week data for the living donor group.
Origin of neutrophils and macrophages in murine grafts
We previously demonstrated a significant increase in the infiltration of neutrophils and macrophages in mouse donor hearts following BD 20 . The above human data similarly shows increased infiltration of neutrophils and macrophages in the BD vs. living donor organ prior to transplantation, and also that these increases persist one week post transplantation. We therefore investigated whether donor-derived inflammatory cells persist in the BD donor organ after transplantation. Using a pan-GFP mouse as BD donor, we assessed GFP+ neutrophils and GFP+ macrophages in grafts at time 0 (following brain death, but prior to implantation), and at 6 and 48 hours post transplantation into syngeneic recipients. At time 0, neutrophils and macrophages were present within vessels, at the epicardial surface, and in the subvascular space as previously grafts from BD donors remained elevated for at least a week post-transplant, wh he e erea ea as in in n l l liv iv ivin in ing g donor grafts the level of positive cells were not significantly different at 10 minutes postt e epe pe perf rf rfu us usio io ion n n th th than n i i in n n n normal heart controls (p ( ( > 0.05 05 05). We did not ha ha ave v a acc cc cce ess to one-week data for h h he li living don nor or gr r roup up p.
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We previousl sly y y de de d mo mo mons ns n tr tr t at ted ed ed a a s s sig ig igni ni ifi f f ca ca ant nt nt i inc nc ncr r rea ea e se se se i in n n th h he e e in in infi fi filt t tra ra rati ti t on on n o o of f f ne ne neut ut utro roph ph phil il ils s s an an and described 20 . We were, however, unable to detect any GFP+GR1+ or GFP+Mac-3+ cells in grafts at either time point post transplantation (supplemental Figure 1) . These data indicate that while BD increases donor organ inflammatory cell burden prior to transplantation, the main source of neutrophils and macrophages post-transplantation are recipient derived.
Discussion
Donor organ injury induced by BD and IRI are considered to be important factors in delayed graft function and the accelerated onset of graft rejection following transplantation [32] [33] [34] . Here, we investigated the role of complement in BD-associated IRI of transplanted hearts. Using our recently described murine model of BD, we show that donor BD enhances complement activation and exacerbates IRI in cardiac isografts, and reduces cardiac allograft survival. We
show that these findings correlate with clinical data obtained from analysis of human cardiac biopsies, and that in contrast to BD donor human hearts, there is minimal or absent complement activation in living donor human hearts, both at the time of organ procurement and at 10 minutes post-reperfusion. Furthermore, we demonstrate that a site-specific targeted complement inhibitor administered to recipient mice effectively protects cardiac grafts against BD-exacerbated IRI.
Previous studies in animal models have shown that BD is associated with cardiac injury that is thought to exacerbate IRI and rejection 32, 35, 36 , and we have shown a role for complement in BD induced cardiac injury in mice 20 . In addition, previous studies in rat models of BD and kidney transplantation have demonstrated that BD induces systemic and local (renal) complement activation 17 . It was also recently shown that treatment of BD donor rats with the systemic complement inhibitor, sCR1, improved renal graft function in the early post transplant period and diminished graft mRNA levels of some cytokines 17 . Nevertheless, a key consideration ecently described murine model of BD, we show that donor BD enhances comp ple l leme m m nt nt nt activation and exacerbates IRI in cardiac isografts, and reduces cardiac allograft survival. We f f h how ow ow t t tha ha hat t t th th the ese fi fi fin nd ndings correlate with clinical d d da at a a a a obtained from m m ana aly ly lys si s s of human cardiac b bi iop p psi s es, and th th ha a at i i in co cont nt ntra ra ast st st to to o B BD D D do dono no or hu hu um m man h he eart ts ts, , th th her ere e is is m m min inim im ima al l o or r r a ab abse sent nt n c c com om mpl pl plem em me e ent ac cti ti tiva va vati ti tion on i i in n n li livi ving ng ng d do on ono or or hu huma ma man n n he he hear art ts ts, bo bo bot th th a a at t t th th he e ti t me me me o o of f f or or rga ga g n n n pr pr proc oc ocur urem emen en e t t t an an nd d d a at 1 1 10 0 mi min nu nute tes post-reperfusi si ion on on. Fu Fu Furt rthe he herm m mor or ore, e e w w we e e de de d mo mo mons ns nstr tr trat at ate e e th th hat at a a a a sit it ite-e-e sp sp spec ec cif if ific ic i t t tar ar arge ge gete te ted d d co co c mp mp mple le leme me m nt inhibitor r r for donor therapy is that any intervention should not impact the successful utilization of all potential organs. This is a potential limitation of complement inhibition in the donor, since it is not known if all donor organs would benefit from such therapy (refer to introduction). Here we show that complement inhibition in the recipient immediately following donor organ implantation significantly ameliorates cardiac graft damage, and returns inflammation and injury profiles in grafts from BD donors to that seen in grafts from living donors. In these studies, we utilized a targeted complement inhibitor, CR2-Crry. The CR2 moiety of this fusion protein binds to the C3 cleavage products iC3b and C3d that are deposited at sites of complement activation, which in the current model is the transplanted heart. We have previously shown that multiple doses of CR2-Crry have minimal effect on serum complement activity and, unlike even a single dose of a systemic inhibitor, does not enhance host susceptibility to infection 25 . This is an important consideration in a transplant recipient who will be heavily immunosuppressed.
Although not examined in the context of BD, another strategy that has been investigated to reduce renal IRI after transplantation, is perfusion of the donor kidney with a derivative of sCR1 that contains a myristoylated peptide (APT070) and that targets to cell membranes, albeit nonspecifically. Pre-treatment of rat kidneys with APT070 improved post-transplant outcome 36 .
Nevertheless, while this approach is specific to the transplanted organ, further administration to the recipient is not possible without systemically inhibiting complement. This constraint does not apply to CR2-mediated site-specific targeting, and prolonged complement inhibition in the recipient may be beneficial since complement is also implicated in acute allograft rejection. Of note, a CR2-targeted inhibitor of the alternative complement pathway, TT30 (human CR2-fH), is currently in phase I clinical trials for paroxysmal nocturnal hemoglobinuria (http://clinicaltrials.gov/ct2/results?term=tt30).
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The increased cardiac injury (histology scores and serum troponin) in murine grafts from BD vs. living donors correlates directly with significantly increased numbers of infiltrating inflammatory cells, as determined by MPO levels, immunohistochemistry and graft chemokine levels. We demonstrate that BD is also associated with a significant elevation of infiltrating inflammatory cells in human cardiac grafts, which may contribute to poorer clinical outcome of grafts from BD donors. In the human samples, we show that macrophages are elevated at all time points in BD compared to living donor heart biopsies. Furthermore, this increase in cellular infiltrate in BD hearts persists one-week post transplantation. One-week post-transplant biopsies from the living donor group were not available, but cell numbers in living donor graft biopsies are not significantly higher than in control biopsies at 10 minutes post-reperfusion. Our studies using pan-GFP donor mice show elevated numbers of neutrophils and macrophages in BD donor hearts prior to transplantation, and this finding is in keeping with our previous observations 20 .
However, while the increased numbers of neutrophils and macrophages seen in mouse BD donor organs persisted after transplantation, further analysis indicated the infiltrating cells were of recipient origin, and we were unable to detect any donor-derived inflammatory cells within the grafts at 6 and 48 hrs post transplantation. This was an unexpected finding. While the absence of donor-derived neutrophils may be easier to explain given their relatively short life span, macrophages may reside in tissues for many weeks. It is possible that macrophages migrate out of the graft early post transplantation and act as antigen presenting cells, which may accelerate graft recognition and rejection, a hypothesis supported by the increased tempo of rejection seen in recipients of brain dead donor hearts. Further studies to delineate the role of donor macrophages in allorecognition are warranted, but fall beyond the scope of this study.
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i ivi vi ving ng ng d donor or rs, s, s, and nd p pre r vi viou ous s clin inic ical al stu udi ies e hav ave e s sh sho own th that at recip ip pie ient ts s of of livin ing g dono nor r gr graf a ts have a a re e edu d ced risk of f f p p prim mar ary y gr graf af aft t f fail l lur ure e an an nd a ac cu u ute r re ej je ect tio io ion, n, n, a a as we ell a as a de e ela ay ye yed d ons s set t t o of f c c ch hro on ni ic ic e eje ject ct ctio io ion n n. T T Th he he d d dat at ata a a su su sugg gg gges es est t th hat at at c c co om ompl plem em men en ent t t i i inh nh nhib ib ibit it itio io ion n ma ma may y y be be be u uti ti tili li lize ze zed d d to to to a ame me eli li lior or ora at ate e BD BD BD exacerbated d IR IR IRI, I, I a and nd nd t t tre re ea atme me men nt o of f f t the he h r rec ec ecip i ipie ie i nt nt w w wil ill l l m m miti ti iga g gate te e p po o f f f te tent tia ia ial l l co co comp mpli lica ca ati tion on ons s s o of donor In the allograft experiment, the mean difference between groups MAP values over time was 0.7 mmHg (95% confidence interval: -7.2 to 8.7, p=0.83). Differences between living vs. BD+CR2-Crry and living vs. BD Sham were not significant.
Results expressed as Mean ± SE; (n=4-6). 
